Stocks and Investing Stocks and Investing
Tue, July 31, 2018
Mon, July 30, 2018
Fri, July 27, 2018
Thu, July 26, 2018

Carter Gould Maintained (BIIB) at Strong Buy with Increased Target to $395 on, Jul 26th, 2018


Published on 2024-10-26 07:10:52 - WOPRAI, Carter Gould
  Print publication without navigation


Carter Gould of UBS, Maintained "Biogen Inc." (BIIB) at Strong Buy with Increased Target from $354 to $395 on, Jul 26th, 2018.

Carter has made no other calls on BIIB in the last 4 months.



There are 5 other peers that have a rating on BIIB. Out of the 5 peers that are also analyzing BIIB, 2 agree with Carter's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Skorney of "Baird" Maintained at Hold with Increased Target to $348 on, Wednesday, July 25th, 2018
  • Geoff Meacham of "Barclays" Maintained at Hold with Increased Target to $320 on, Wednesday, July 25th, 2018


These are the ratings of the 3 analyists that currently disagree with Carter


  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $392 on, Wednesday, July 25th, 2018
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $396 on, Monday, July 23rd, 2018
  • Robyn Karnauskas of "Citigroup" Upgraded from Hold to Strong Buy and Held Target at $371 on, Friday, July 6th, 2018